Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 63

Sort by

Sort Order Select

Journal Articles

Unveiling Clinical Potential: Exploring Cytogenomic Aberrations through Optical Genomic Mapping in Multiple Myeloma

J Christine Ye, Guilin Tang, Oren Pasvolsky, Melody R. Becnel, Mahmoud R. Gaballa, Krina K. Patel, Hans C. Lee, Sheeba K. Thomas, Donna M. Weber, Pei Lin, Robert Z. Orlowski

Blood (2024) 144 (Supplement 1): 1971.

https://doi.org/10.1182/blood-2024-212346

Published: 2024

Journal Articles

Outcomes of Patients with Multiple Myeloma with Deletion 1p Following Autologous Stem Cell Transplant

Blood (2024) 144 (Supplement 1): 3344.

https://doi.org/10.1182/blood-2024-203700

Published: 2024

Journal Articles

Myeloid Progenitor Cells with Preleukemic Immunophenotypes Are Common in Myelodysplasia-Related and NPM1- mutated Acute Myeloid Leukemia and Should Not be Interpreted As Measurable Residual Disease

Blood (2024) 144 (Supplement 1): 4336.

https://doi.org/10.1182/blood-2024-209462

Published: 2024

Journal Articles

Cohesin Complex Gene Mutated Acute Myeloid Leukemia (AML) Responds Favorably to Venetoclax Based Frontline Therapy

Blood (2024) 144 (Supplement 1): 4306.

https://doi.org/10.1182/blood-2024-208602

Published: 2024

Journal Articles

Predictors for Time-to-First-Treatment in Patients with Del(17p) and/or TP53 -Mutated Chronic Lymphocytic Leukemia

Anjali Lankford, Mahesh Swaminathan, Amrit S. Gonugunta, Himachandana Atluri, Hannah Goulart, Koji Sasaki, Guilin Tang, Rashmi Kanagal-Shamanna, Jan A. Burger, Alessandra Ferrajoli, Hagop Kantarjian, William G. Wierda, Nitin Jain

Blood (2024) 144 (Supplement 1): 3246.

https://doi.org/10.1182/blood-2024-208974

Published: 2024

Journal Articles

Outcomes of Adult Patients with Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia (B-ALL) Having Myeloid Type Mutations Treated with Inotuzumab/Blinatumomab Containing Frontline Regimens

Jayastu Senapati, Hagop M. Kantarjian, Clark Robinson, Koichi Takahashi, Nitin Jain, Fadi G. Haddad, Courtney D. DiNardo, Sanam Loghavi, Guilin Tang, Guillermo Montalban-Bravo, Tapan M. Kadia, Naval Daver, Koji Sasaki, Zena Komrokji, Rebecca Garris, Guillermo Garcia-Manero, Farhad Ravandi, Nicholas J. Short, Elias Jabbour

Blood (2024) 144 (Supplement 1): 1461.

https://doi.org/10.1182/blood-2024-204181

Published: 2024

Journal Articles

Phase I/II Study of Quizartinib, Venetoclax, and Decitabine Triple Combination in FLT3-ITD Mutated AML

Blood (2024) 144 (Supplement 1): 4263.

https://doi.org/10.1182/blood-2024-204296

Published: 2024

Journal Articles

Genomic Profiling of T-Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL) for Identification of Driver Aberrations Using Combined Next Generation Sequencing and Optical Genome Mapping in Clinical Diagnostic Laboratory

Iman Sarami, Ruchi Singhal, Mark Routbort, Koji Sasaki, Daniel Domogala III, Gokce A. Toruner, Shibu Ninan, Nitin Jain, Keyur P. Patel, Elias Jabbour, Hagop M. Kantarjian, Carlos E. Bueso-Ramos, L. Jeffrey Medeiros, Raja Luthra, Guilin Tang, Rashmi Kanagal-Shamanna

Blood (2024) 144 (Supplement 1): 4224.

https://doi.org/10.1182/blood-2024-211561

Published: 2024

Journal Articles

Application of Next-Generation Cytogenetics in a Clinical Laboratory for Diagnostic Work-up of Myelodysplastic Syndromes/Neoplasms (MDS)

Anindita Ghosh, Guilin Tang, Hui Yang, Koji Sasaki, Gokce A. Toruner, Juan Jose Rodriguez-Sevilla, Raja Luthra, Danielle Hammond, L. Jeffrey Medeiros, Carlos E. Bueso-Ramos, Guillermo Montalban-Bravo, Kelly S. Chien, Guillermo Garcia-Manero, Rashmi Kanagal-Shamanna

Blood (2024) 144 (Supplement 1): 7519.

https://doi.org/10.1182/blood-2024-211967

Published: 2024

Journal Articles

Conditioning with Busulfan + Melphalan Versus Single-Agent Melphalan for Patients with Multiple Myeloma Receiving Autologous Stem Cell Transplantation: A Propensity Score-Matched Analysis

Blood (2024) 144 (Supplement 1): 7019.

https://doi.org/10.1182/blood-2024-203529

Published: 2024

Journal Articles

Second Line Treatment in Patients with Multiple Myeloma Progressing after Bortezomib, Lenalidomide, Dexamethasone Induction, Autologous Transplant and Lenalidomide Maintenance

Blood (2024) 144 (Supplement 1): 7018.

https://doi.org/10.1182/blood-2024-203404

Published: 2024

Journal Articles

Characteristics and Survival Outcome of Patients with Isolated 11q Deletion Myelodysplastic Syndromes

Blood (2024) 144 (Supplement 1): 6746.

https://doi.org/10.1182/blood-2024-208444

Published: 2024

Journal Articles

Acalabrutinib with Rituximab Is Highly Effective First Line Treatment for Older Patients with Mantle Cell Lymphoma

Blood (2024) 144 (Supplement 1): 3038.

https://doi.org/10.1182/blood-2024-206042

Published: 2024

Journal Articles

Phase 1b/2 Study of Magrolimab (Magro), Azacitidine (AZA) and Venetoclax (VEN) in Patients (pts) with Newly Diagnosed (ND) Older/Unfit or High Risk Acute Myeloid Leukemia (AML) and Relapsed Refractory (R/R) AML: Final Clinical Data and Genomic Markers of Resistance/Relapse

Blood (2024) 144 (Supplement 1): 735.

https://doi.org/10.1182/blood-2024-203706

Published: 2024

Journal Articles

Genomic and Transcriptomic Profiles of Blastoid and Pleomorphic Mantle Cell Lymphoma Are Distinct from Classic Histology Mantle Cell Lymphoma

Preetesh Jain, Holly A Hill, Chi Young Ok, Alexander Nesmalov, Vitaly Segodin, Dmitry Tabakov, Nikita Kotlov, Pavel Zemskiy, Eleonora Belykh, Krystle Nomie, Ahmed Fetooh, Rashmi Kanagal-Shamanna, Fatima Z Jelloul, Guilin Tang, Francisco Vega, Nathan Fowler, Christopher R. Flowers, Michael L. Wang

Blood (2023) 142 (Supplement 1): 3001.

https://doi.org/10.1182/blood-2023-181319

Published: 2023

Journal Articles

IFNγ Signaling in Acute Myeloid Leukemia Mediates Immunomodulation and Reveals Therapeutic Strategies

Blood (2023) 142 (Supplement 1): 2796.

https://doi.org/10.1182/blood-2023-175010

Published: 2023

Journal Articles

Phase I/II Study of Quizartinib, Venetoclax, and Decitabine Triple Combination in FLT3-ITD Mutated AML

Blood (2023) 142 (Supplement 1): 158.

https://doi.org/10.1182/blood-2023-186699

Published: 2023

Journal Articles

Six Years Follow up of Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hyper CVAD/MTX in Patients (age ≤ 65 years) with Previously Untreated Mantle Cell Lymphoma - Phase-II Window-1 Clinical Trial

Preetesh Jain, Hun Ju Lee, Jason Westin, Loretta J. Nastoupil, Luis Fayad, Ranjit Nair, Swami P. Iyer, Rashmi Kanagal-Shamanna, Ahmed Fetooh, Holly A Hill, Chi Young Ok, Wendy Chen, Onyeka Oriabure, Lei Feng, Guilin Tang, Francisco Vega, Maria Badillo, Christopher R. Flowers, Michael L. Wang

Blood (2023) 142 (Supplement 1): 1688.

https://doi.org/10.1182/blood-2023-181312

Published: 2023

Journal Articles

Daratumumab-Based Maintenance in Patients with Relapsed Multiple Myeloma after Salvage Autologous Hematopoietic Stem Cell Transplantation

Blood (2023) 142 (Supplement 1): 7070.

https://doi.org/10.1182/blood-2023-189109

Published: 2023

Journal Articles

Characterizing Inferred Functional and Phenotypical States of Newly Diagnosed Acute Myeloid Leukemia from Single Cell Transcriptomic Profiling

Bofei Wang, Christopher Ly, Enes Dasdemir, Fatima Z Jelloul, Poonam N Desai, Pamella Borges, Jessica Lynn Root, Guilin Tang, Preethi Gunaratne, Sreyashi Basu, Sonali Jindal, Yulong Chen, Khalida M Wani, Alexander J Lazar, Padmanee Sharma, Patrick K Reville, Hussein A Abbas

Blood (2023) 142 (Supplement 1): 2938.

https://doi.org/10.1182/blood-2023-178345

Published: 2023

NARROW

Unveiling Clinical Potential: Exploring Cytogenomic Aberrations through Optical Genomic Mapping in Multiple Myeloma

Outcomes of Patients with Multiple Myeloma with Deletion 1p Following Autologous Stem Cell Transplant

Myeloid Progenitor Cells with Preleukemic Immunophenotypes Are Common in Myelodysplasia-Related and NPM1- mutated Acute Myeloid Leukemia and Should Not be Interpreted As Measurable Residual Disease

Cohesin Complex Gene Mutated Acute Myeloid Leukemia (AML) Responds Favorably to Venetoclax Based Frontline Therapy

Predictors for Time-to-First-Treatment in Patients with Del(17p) and/or TP53 -Mutated Chronic Lymphocytic Leukemia

Outcomes of Adult Patients with Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia (B-ALL) Having Myeloid Type Mutations Treated with Inotuzumab/Blinatumomab Containing Frontline Regimens

Phase I/II Study of Quizartinib, Venetoclax, and Decitabine Triple Combination in FLT3-ITD Mutated AML

Genomic Profiling of T-Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL) for Identification of Driver Aberrations Using Combined Next Generation Sequencing and Optical Genome Mapping in Clinical Diagnostic Laboratory

Application of Next-Generation Cytogenetics in a Clinical Laboratory for Diagnostic Work-up of Myelodysplastic Syndromes/Neoplasms (MDS)

Conditioning with Busulfan + Melphalan Versus Single-Agent Melphalan for Patients with Multiple Myeloma Receiving Autologous Stem Cell Transplantation: A Propensity Score-Matched Analysis

Second Line Treatment in Patients with Multiple Myeloma Progressing after Bortezomib, Lenalidomide, Dexamethasone Induction, Autologous Transplant and Lenalidomide Maintenance

Characteristics and Survival Outcome of Patients with Isolated 11q Deletion Myelodysplastic Syndromes

Acalabrutinib with Rituximab Is Highly Effective First Line Treatment for Older Patients with Mantle Cell Lymphoma

Phase 1b/2 Study of Magrolimab (Magro), Azacitidine (AZA) and Venetoclax (VEN) in Patients (pts) with Newly Diagnosed (ND) Older/Unfit or High Risk Acute Myeloid Leukemia (AML) and Relapsed Refractory (R/R) AML: Final Clinical Data and Genomic Markers of Resistance/Relapse

Genomic and Transcriptomic Profiles of Blastoid and Pleomorphic Mantle Cell Lymphoma Are Distinct from Classic Histology Mantle Cell Lymphoma

IFNγ Signaling in Acute Myeloid Leukemia Mediates Immunomodulation and Reveals Therapeutic Strategies

Phase I/II Study of Quizartinib, Venetoclax, and Decitabine Triple Combination in FLT3-ITD Mutated AML

Six Years Follow up of Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hyper CVAD/MTX in Patients (age ≤ 65 years) with Previously Untreated Mantle Cell Lymphoma - Phase-II Window-1 Clinical Trial

Daratumumab-Based Maintenance in Patients with Relapsed Multiple Myeloma after Salvage Autologous Hematopoietic Stem Cell Transplantation

Characterizing Inferred Functional and Phenotypical States of Newly Diagnosed Acute Myeloid Leukemia from Single Cell Transcriptomic Profiling

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only